The Crone Law Group, P.C. Advises TenX Keane Acquisition on its Initial Business Combination with Citius Pharmaceuticals, Inc.

New York, NY. August 14, 2024 – The Crone Law Group P.C. (CLG) acted as advisor for TenX Keane Acquisition, a publicly traded special purpose acquisition company (TenX), in its initial business combination. TenX completed its merger with the oncology subsidiary of Citius Pharmaceuticals, Inc. (Citius Pharma) (Nasdaq: CTXR), a late-stage biopharmaceutical company, on August 12, 2024. TenX now operates as Citius Oncology, Inc. and began trading on the Nasdaq stock exchange under the ticker symbol ‘CTOR’, on August 13, 2024. The merger, including assumed stock options, was valued at $775mm.

“This transaction is a testament to our team’s ability to consistently support our clients with sophisticated counsel and personalized service throughout all phases of their business,” said CLG managing partner, Mark Crone.

The CLG team which advised on the transaction was led by M&A Practice Group Leader Tammara Fort and included of counsel Samara Thomas, associate Patrice Malcolm, and partner Eric Mendelson on capital markets matters.